Welcome to our dedicated page for Prometheus Biosciences news (Ticker: RXDX), a resource for investors and traders seeking the latest updates and insights on Prometheus Biosciences stock.
Prometheus Biosciences, Inc. (NASDAQ: RXDX) delivers cutting-edge precision therapeutics for gastrointestinal and autoimmune diseases through its innovative R&D pipeline. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trial progress, strategic partnerships, and regulatory developments.
Access timely reports on milestone achievements including trial phase completions, FDA communications, and collaborative research initiatives. Our curated news collection enables informed tracking of the company’s work in companion diagnostics and targeted treatment solutions.
Key updates cover therapeutic advancements, intellectual property developments, and financial performance indicators. Bookmark this page to maintain current awareness of RXDX’s contributions to precision medicine and its growing impact on patient care standards.
Prometheus Biosciences (Nasdaq: RXDX) announced the appointment of Fred Hassan to its Board of Directors on May 17, 2021. Hassan, a seasoned executive with extensive experience in the pharmaceutical industry, is expected to enhance Prometheus' strategic direction as the company advances its pipeline focused on immune-mediated diseases, particularly inflammatory bowel disease (IBD). His past roles include CEO positions at Schering-Plough and Pharmacia Corporation. Hassan expressed his enthusiasm for Prometheus' potential in transforming treatments for immune-mediated diseases.
Prometheus Biosciences (Nasdaq: RXDX) announced Mark McKenna, President and CEO, will take part in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 10:55 a.m. ET. This San Diego-based clinical-stage biotechnology company focuses on precision medicine for immune-mediated diseases, particularly inflammatory bowel disease (IBD). The event will be accessible via live and archived webcasts on their website.
Prometheus Biosciences (Nasdaq: RXDX) announced significant advancements in its Phase 2 clinical trials, targeting ulcerative colitis and Crohn’s disease with PRA023. The company launched Enroll360™, a patient recruitment platform aimed at enhancing clinical trial efficiency. Additionally, Prometheus successfully completed an oversubscribed IPO, raising $218.5 million. As of March 31, 2021, cash reserves reached $311.2 million, up from $54.2 million at the end of 2020. However, R&D expenses rose to $7.8 million, indicating increased investment in product development.
Prometheus Biosciences (Nasdaq: RXDX) announced the closing of its initial public offering of 11.5 million shares at $19.00 per share, generating approximately $218.5 million in gross proceeds before expenses. This includes a full exercise of underwriters' option for an additional 1.5 million shares. The IPO aims to enhance financial flexibility for the development of novel therapeutic products for inflammatory bowel disease. The company's common stock is now traded on the Nasdaq Global Select Market.
Prometheus Biosciences, Inc. (Nasdaq: RXDX) has successfully priced its upsized initial public offering (IPO) of 10 million shares at $19.00 each, aiming to raise approximately $190 million before expenses. The shares will trade on the Nasdaq Global Select Market starting March 12, 2021, with the offering expected to close on March 16, 2021. Additionally, underwriters have a 30-day option to purchase 1.5 million extra shares. The company specializes in precision medicine for inflammatory bowel disease (IBD).
FAQ
What is the market cap of Prometheus Biosciences (RXDX)?
